FRANKFURT, March 6 (Xinhua) -- German science and technology giant Merck Group reported a return to growth in 2024, with net sales rising 0.8 percent to 21.16 billion euros (22.8 billion U.S. dollars) ...

Merck KGaA expects earnings and sales growth this year after reporting a rise in annual earnings on temporarily reduced ...

Germany’s Merck MRK-2.82%decrease; red down pointing triangle KGaA said it is in advanced talks for a potential acquisition of SpringWorks Therapeutics SWTX-3.57%decrease; red down pointing ...

Germany’s Merck KGaA (MRK: DE) returned to profitable growth in 2024 and delivered on its guidance for the year.

On Monday, Germany-based Merck KGaA (OTC:MKGAF) (OTC:MKKGY) reacted to press reports and confirmed advanced discussions with SpringWorks Therapeutics Inc (NASDAQ:SWTX), which has a market ...

Merck, in a statement, said its negotiations to buy SpringWorks are ongoing, confirming an earlier report from Reuters. The Darmstadt, Germany-based company said that no legally binding agreement ...

Germany's Merck KGaA said it is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical company that specializes in rare diseases and cancer.

India], March 11: Merck Foundation, the philanthropic arm of Merck KGaA Germany, together with First Ladies of Africa and ...

Merck Germany also confirmed that no legally binding agreement has been entered into. There is no certainty that any transaction will materialize. Furthermore, critical conditions have yet to be met.

Merck KGaA said it appointed two new members to the executive board for the life science and healthcare business sectors, along with a newly-created chief people officer role. The German ...

Merck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...